ELMSFORD, N.Y., Feb. 11, 2014 /PRNewswire/
-- BioScrip®, Inc. (NASDAQ: BIOS) ("BioScrip")
today announced that it has completed its private placement of
$200.0 million aggregate principal
amount of 8.875% senior unsecured notes due 2021.
The Company used approximately $194.5
million of the net proceeds of the offering to pay a portion
of the amounts outstanding on its $75 million senior secured
first-lien revolving credit facility, its $150 million senior secured first-lien delayed
draw term loan B and its $250 million
senior secured first-lien term loan B.
The notes and related guarantees were sold in a private
placement, solely to qualified institutional buyers in reliance on
Rule 144A under the Securities Act of 1933, as amended (the
"Securities Act"), or outside the United
States to persons other than "U.S. persons" in compliance
with Regulation S under the Securities Act. The notes and related
guarantees have not been registered under the Securities Act or the
securities laws of any other jurisdiction and may not be offered or
sold in the United States absent
registration or an applicable exemption from the registration
requirements.
This notice does not constitute an offer to sell the notes, nor
a solicitation for an offer to purchase the notes, in any
jurisdiction in which such offer or solicitation would be unlawful.
Any offer of the notes will be made only by means of a private
offering memorandum.
About BioScrip, Inc.
BioScrip, Inc. provides comprehensive infusion and home care
solutions. By partnering with patients, physicians,
healthcare payors, government agencies and pharmaceutical
manufacturers, we are able to provide access to infusible
medications and management solutions. Our goal is to optimize
outcomes for chronic and other complex healthcare conditions and
enhance the quality of patient life. BioScrip brings clinical
competence in providing high-touch, comprehensive infusion and
nursing services to patients in the most convenient ways
possible. Through our customer services and treatments we aim
to ensure the best possible therapy outcome.
Contacts:
Hai Tran
BioScrip, Inc.
952-979-3768
SOURCE BioScrip, Inc.